

PREFACE

The idea that cell membranes and intracellular signal cascades could become the targets of antitumor drugs has come of age. The increase in our knowledge of the role of the membrane and cell signalling in the control of cell growth, and the appreciation of the complexity of the structure and function of this organelle suggest the existence of fertile ground for the drug discoverer. By bringing together basic scientists and experimental chemotherapists as well as clinicians at this, the first international meeting on the subject, we hope to accelerate the progress of the treatment of cancer by novel strategies and to fire the imaginations of those who are considering entering a new and exciting area of drug research.

The Organizing Committee

Jean-Pierre Abita	Garth Powis
Wolfgang E. Berdel	Timothy J. Rink
John A. Hickman	Anne P. Simmonds
Edward J. Modest	Thomas R. Tritton
Garth L. Nicolson	Paul Workman

ACKNOWLEDGMENTS

The organizers gratefully acknowledge the following conference sponsors:

American Association for Cancer Research
 British Association for Cancer Research
 European Organization for Research and Treatment of Cancer
 (Pharmacokinetics and Metabolism Group)
 Asta (Federal Republic of Germany)
 Boehringer Mannheim (Federal Republic of Germany)
 Cancer Research Campaign (UK)
 E. I. du Pont de Nemours & Co., Inc. (USA)
 Farmitalia Carlo Erba (Italy)
 Glaxo (UK)
 Hoffmann La Roche (Switzerland)
 Hoffmann La Roche, Inc. (USA)
 ICI Pharmaceuticals (UK)
 Imperial Cancer Research Fund (UK)
 Kirby Warrick Pharmaceuticals Ltd. (UK)
 Laboratoire Bristol Myers (France)
 Laboratoire Roger Bellon (France)
 Lederle Laboratories (UK)
 Eli Lilly (Federal Republic of Germany)
 Eli Lilly (UK)
 Lilly Research Laboratories (USA)
 Sandoz Ltd. (Switzerland)
 Schering-Plough Corporation (USA)
 Smith Kline & French (UK)
 Sterling Drug
 Waters Chromatography Division of Millipore UK Ltd.
 Wellcome Research Laboratories (UK)
 Xenova (UK)